This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Resources - Articles

The Comprehensive Package

It is widely recognised that the economic downturn has taken a turn for the better; this can be demonstrated across a number of industries, pharmaceutical development being one.

In the last two years, new chemical entity (NCE) approvals have risen to an extent not seen since the early 1990s. This is encouraging news for an industry that has gone through a significant period of change. In 2012, the US FDA signed off a total of 58 new drug announcements, an impressive rise on previous years. What is surprising about this figure is the increase in approvals of cold chain products, which made up almost 38% of new drug announcements.

With an influx in specialty pharmaceuticals, and orphan and oncology drugs, as well as flu-related vaccines this figure will continue to rise, and along with it the complexities of the drug product life cycle for compounds with special requirements.

Read more about this here

October 12, 2015


PCI Unveils Clinical Center of Excellence

Expanded Clinical Services Facility in Rockford, IL to Support Growth and Flexibility with 30,000 additional sq ft We have officially... View Article

Significant Investments at Ireland Site

PCI Strengthens Position in Europe with Investment in Ireland Latest development at Dublin site positions it at forefront of EU... View Article

x